Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | EVP & General Counsel | March 17, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date March 17, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,231 |
Reported balance
After 2026-03-17 transaction · row 1
1 source rowRow 1 · 2026-03-17 · Tax withholding · Disposed 8,840 · Balance 68,231 F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 21:14 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 13,976 | $34.92 | $488,099.22 |
DisclosureSEC source: 0002061438-26-000006 · form4-03202026_090345.xml · nonDerivative · entry 1 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,071 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.74 to $35.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 17, 2026 Filed Apr 3, 2026 20:46 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 8,840 | $35.72 | $315,764.80 |
DisclosureSEC source: 0002061438-26-000009 · form4-04032026_080415.xml · nonDerivative · entry 1 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,231 F1 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of restricted stock units. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 20:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 6,224 | $36.65 | $228,109.60 |
DisclosureSEC source: 0002061438-26-000004 · form4-03112026_080318.xml · nonDerivative · entry 1 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,047 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Tax withholdingCommon Stock | 2,781 | $46.75 | $130,011.75 |
DisclosureSEC source: 0002061438-26-000002 · form4-02122026_040219.xml · nonDerivative · entry 3 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,271 F4 · shares: Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,005 | $0.00 | $0.00 |
DisclosureSEC source: 0002061438-26-000002 · form4-02122026_040219.xml · nonDerivative · entry 2 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,052 F3 · shares: Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 9,005 performance share units ("PSUs") granted in the Issuer's 2025 fiscal year. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:30 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 22,194 | $0.00 | $0.00 |
DisclosureSEC source: 0002061438-26-000002 · form4-02122026_040219.xml · nonDerivative · entry 1 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,047 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. F2 · balance_after: Includes 404 shares acquired on January 16, 2026 under the Issuer's employee stock purchase plan. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:36 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 68,449 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-005904 · form4.xml · nonDerivative · entry 1 Dieter David · CIK 0002061438 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,449 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Thirty-three percent (33%) of the RSUs shall vest on March 17, 2026, with the balance vesting in two annual installments thereafter, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.